Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 14, Issue 12, 2011, Pages 912-917

  Xu, Chong'an ^a   Wang, Xiaojie ^a   Zhang, Ye ^a   Li, Lin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy sensitivity; Lung neoplasms; Single nucleotick polymorphism; X ray repair cross complementing protein 1 (XRCC1); X ray repair cross complementing protein 3 (XRCC3)

Indexed keywords

GENOMIC DNA; PLATINUM DERIVATIVE; XRCC1 PROTEIN; XRCC3 PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; DNA REPAIR; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 83455212167     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.12.03     Document Type: Article

References (18)

1. Fisher MD, D'Orazio A. Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer, 2000, 2(1): 21-22.
2. Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin and carboplatin-based doublet chemotherapeutic regimens versus nonplatinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer, 2008, 59(1): 1-11.
3. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol, 2009, 5(7): 745-755.
4. Nisato RE, Tille JC, Pepper MS. Lymphangiogenesis and tumor metastasis. Thromb Haemost, 2003, 90(4): 591-597.
5. Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer, 2006, 54(3): 267-283.
6. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol, 2007, 22(13): 2594-2601.
7. Luun RM, Langlois RG, Hsieh LL, et al. XRCC1 polymorphisms effects on aflatoxin B1-DNA adducts and glycophorin a variant frequency. Cancer Res, 1999, 59(11): 2557-2561.
8. Rosell R, Lord RV, Taron M, et al. DNA repair and cisplatin resistance in nonsmall-cell lung cancer. Lung Cancer, 2002, 38(3): 217-227.
9. Butkiewicz D, Rusin M, Enewold L, et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis, 2001, 22(4): 593-597.
10. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst, 2000, 92(6): 440-441.
11. Shen MR, Jones M, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 1998, 58(4): 604-608.
12. Wang ZH, Miao XP, Tan W, et al. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Chin J Cancer, 2004, 23(8): 865-868.
13. Hong CY, XU Q, Yue Y, et al. Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism. 2009, 14(12): 1291-1297.
14. Yao CY, Huang XE, Li C, et al. Relationship between the combination of XRCC1 and XPD gene polymorphisms with platinum-based chemotherapy in advanced non-small cell lung cancer. 2010, 30(6): 391-395.
15. Zhao W, Hu LM, Wang C, et al. Relationship of XRCC1, PARP1 and APE1 polymorphisms with efficacy of platinum-based chemotherapy for patients with advanced non-small cell lung cancer. Acta universitatis medicinalis nanjing (Natural Science). 2011, 31(7): 1021-1026.
16. Zhang ZL, Zhou CC, Zhang J, et al. Relationship between polymorphisms of DNA repair gene XRCC3 and susceptibility to lung cancer. Chin J Tuberc Respir Dis, 2007, 30(12): 936-940.
17. Hang M, Cai L. XRCC3 polymorphisms associated with lung cancer: a meta analysis. Fujian Med Univ, 2010, 44(4): 295-269.
18. Ren SX, Zhou CC, Zhou SW, et al. Predictive role of ERCC1 and XRCC3 gene polymorphism on response of platinum-based chemotherapy in advanced NSCLC. J Oncol, 2009, 15(8): 706-710.